Aclaris Therapeutics

Aclaris Therapeutics Advances Immuno-Inflammatory Pipeline, Targets Four Clinical Programs in 2026

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) reported third-quarter 2025 financial results and outlined continued progress across its expanding immuno-inflammatory pipeline, emphasizing execution in both oral kinase inhibitors and …

Aclaris Therapeutics Advances Immuno-Inflammatory Pipeline, Targets Four Clinical Programs in 2026 Read More